منابع مشابه
COX-1 and COX-2 products in the gut: therapeutic impact of COX-2 inhibitors.
Despite the considerable range of newly identified disease modifying approaches to the control of the inflammatory process reported over the past 10–20 years, only a few have yet gained widespread clinical acceptance. In contrast, the very recent advent of the class of anti-inflammatory agents termed COX-2 selective inhibitors is already having a significant impact on current clinical prescribi...
متن کاملCOX-2 inhibitor.
he developed severe psoriasis responsive only to repeated courses of the then newly available PUVA (psoralen plus UVA radiation) therapy. Between 1973 and 1993 he received PUVA once a week. During treatment no genital protection was used although he had never received UV therapy directly to the genital area. Two years after the onset of psoriasis he developed peripheral inflammatory arthritis. ...
متن کاملCOX-2 inhibitors.
Cyclooxygenase-2 (COX-2) inhibitors constitute a new group of non-steroidal anti-inflammatory drugs (NSAIDs) which, at recommended doses, block prostaglandin production by cyclooxygenase-2, but not by cyclooxygenase-1. Two COX-2 inhibitors are currently available in Australia--celecoxib, which is taken twice daily, and rofecoxib, which is taken once daily. Both drugs act rapidly in providing pa...
متن کاملGrowth stimulation of COX-2-negative pancreatic cancer by a selective COX-2 inhibitor.
Cyclooxygenase 2 (COX-2) inhibitors are promising antiangiogenic agents in several preclinical models. The aim of the present study was to evaluate the effect of selective COX-2 inhibitors on vascular endothelial growth factor (VEGF) production in vitro and angiogenesis and growth of pancreatic cancer in vivo, focusing on putative differences between COX-2-negative and COX-2-positive tumors. VE...
متن کاملHerbal COX-2 Inhibitors: A Natural Alternative
n Sept. 30, 2004, the pharmaceutical giant Merck & Co. Inc. announced a voluntary worldwide withdrawal of VIOXX (rofecoxib), its arthritis and acute pain COX-2 inhibiting medication. The company’s decision was based on data from a new, three-year prospective, randomized, placebo-controlled clinical trial, which showed that after 18 months of use, VIOXX increased relative risk for confirmed card...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nature Reviews Urology
سال: 2016
ISSN: 1759-4812,1759-4820
DOI: 10.1038/nrurol.2016.155